Recombinant Virus
Recombinant Virus Products
Creative Biolabs offers a comprehensive suite of highly optimized, clinically relevant viral vectors, ensuring the right tool for every gene delivery requirement:
Adeno-Associated Virus (AAV)
AAV is a workhorse of in vivo gene therapy, noted for its low immunogenicity and capacity to transduce non-dividing cells for stable, long-term expression.
Lentivirus (LV)
Derived from HIV (with all pathogenicity genes removed), LV vectors are prized for their ability to permanently integrate large gene payloads (up to kb) into the host cell's genome.
Adenovirus (Ad)
Adenoviral vectors possess a large cloning capacity and elicit very high levels of transient expression. They are highly efficient at transducing a broad range of cell types, making them ideal for high-throughput screening.
Retrovirus
These traditional integrating vectors, while often superseded by Lentivirus in modern clinical trials due to safety profile advancements, remain essential tools for certain research and ex vivo applications.
Applications of Our Products
The versatility and high quality of our recombinant viral vectors enable groundbreaking applications across the biomedical landscape:
Gene Therapy for Monogenic Diseases
High-titer AAV vectors are the preferred vehicle for treating inherited disorders such as Spinal Muscular Atrophy (SMA), Leber Congenital Amaurosis (LCA), and Hemophilia, by delivering a functional copy of the deficient gene.
Immuno-Oncology and Cell Therapy
GMP-grade Lentivirus vectors are foundational to the rapid expansion of the CAR-T and TCR-T cell therapy fields, providing stable, long-term genetic modification of patient-derived immune cells to target malignancies.
Vaccinology
Recombinant Adenovirus vectors are successfully utilized as non-replicating vaccine platforms to present antigens for infectious diseases (e.g., certain COVID-19 and Ebola vaccines) and cancer immunotherapy, generating robust cytotoxic T-lymphocyte (CTL) responses.
Drug Discovery and Target Validation
High-quality vectors are essential research tools for loss-of-function (shRNA/miRNA) and gain-of-function studies, providing reliable means to manipulate gene expression for drug target identification and validation in complex biological systems.
Features of Recombinant Virus Vectors
Recombinant viral vectors possess several characteristic features that make them particularly valuable for gene delivery applications. These modified viruses are engineered to retain the natural tropism of their parental strains while exhibiting significantly reduced pathogenicity, creating an optimal balance between efficiency and safety. One of their most significant advantages is the ability to achieve high transduction efficiency across diverse cell types, including both dividing and non-dividing cells, which remains a challenge for many non-viral delivery methods. This broad cellular tropism enables researchers to target specific tissues with precision, making recombinant viruses versatile tools for both in vitro and in vivo applications.
| Vector Type | Insert Capacity | Integration | Expression Duration | Primary Applications |
|---|---|---|---|---|
| Adenovirus | Up to 8 kb | No | Transient | Vaccines, Cancer therapy |
| AAV | <4.7 kb | Rare | Long-term | Gene therapy, Neurological disorders |
| Lentivirus | Up to 8 kb | Yes | Stable | Stable cell lines, Gene editing |
| Retrovirus | Up to 8 kb | Yes | Stable | ex vivo gene therapy, CAR-T cells |
Streamlined Production Process
Our multi-stage, proprietary vector production workflow is optimized for scalability, purity, and turnaround time:
Upstream Processing (USP)
High-density cell culture systems are used for robust host cell growth (e.g., HEK293 lines) and triple-plasmid transfection to maximize vector yield.
Harvest and Lysis
Optimized, gentle harvest and lysis protocols ensure maximum release of high-quality viral particles.
Downstream Processing (DSP)
A multi-step purification train utilizes advanced chromatography followed by tangential flow filtration (TFF).
Final Formulation
Vectors are formulated in a clinically acceptable buffer, sterile-filtered, and subjected to final QC release testing.
Reasons to Choose Creative Biolabs
High Titer and Purity
We guarantee industry-leading vector titers and purity levels, minimizing extraneous proteins and nucleic acids that complicate regulatory review and cause immune responses.
Regulatory Documentation
Our products are accompanied by comprehensive Chemistry, Manufacturing, and Controls (CMC) documentation, including batch records, Certificates of Analysis (CoAs), and process validation reports.
Custom Formulation
We do not offer one-size-fits-all buffers. We execute excipient screening and stability studies tailored to your specific vector and intended route of administration.
Genomic Integrity Assurance
We use quantitative PCR and Next-Generation Sequencing (NGS) to confirm sequence fidelity, orientation, and ITR integrity of the therapeutic cassette in the viral genome.
Suspension Bioreactor Scalability
Our manufacturing process is optimized for suspension cell culture in large-scale stirred-tank bioreactors, providing a proven, linear scale-up pathway.
Robust Freedom-to-Operate Platform
We utilize proprietary and next-generation vector packaging systems and host cell lines, mitigating IP risks and providing our clients with robust freedom-to-operate documentation for commercial deployment.
Customer Review
"Our lab frequently uses recombinant virus for protein expression studies, and this team’s service stands out. Their viruses consistently show high purity—no detectable contaminants—and strong infectivity, which made our cell-based assays more reproducible. Turnaround was just 5 days, faster than we expected, and the technical sheet included clear storage guidelines. Their team also adjusted the virus formulation to fit our cell type, solving a prior issue we had with other providers. We now use them for all our recombinant virus needs."
Dr. Liam Foster
Research Scientist
"For our basic virology research on host-virus interactions, reliable recombinant virus is non-negotiable—and this service delivers. Each batch we’ve ordered has met or exceeded our quality standards, with uniform particle size and stable infectivity over storage. The team was responsive when we requested minor modifications to the virus construct, and the final product worked seamlessly in our transfection experiments. Their transparent pricing and on-time delivery also make planning our lab work much easier."
Kenji Tanaka
Senior Research Associate
Frequently Asked Questions
The selection of an appropriate viral vector depends on several factors, including the target cell type (dividing vs. non-dividing), required duration of expression (transient vs. long-term), insert size, and whether genomic integration is desired or should be avoided. Adenoviruses are ideal for applications requiring high-level but transient expression in dividing and non-dividing cells. AAV vectors provide long-term expression in non-dividing cells with minimal toxicity but have limited packaging capacity. Lentiviruses efficiently transduce both dividing and non-dividing cells with stable genomic integration, while retroviruses are suitable for dividing cells with stable integration. Our technical team can provide detailed guidance on selecting the optimal platform for your specific application.
For transgenes exceeding the approximately 4.7 kb packaging limit of AAV, we offer several validated strategies, including dual-vector systems that reconstitute large genes through different mechanisms. The overlapping approach relies on homologous recombination between co-transduced vectors with shared homologous sequences. The trans-splicing approach utilizes split introns that reassemble at the mRNA level through splicing. The hybrid approach combines elements of both strategies to enhance reconstruction efficiency. Additionally, we can implement minigene designs that eliminate non-essential sequences while preserving functional elements, and we offer capsid engineering to potentially expand packaging capacity in specific serotypes.
We implement multiple safety engineering strategies to minimize risks associated with viral vector applications. For integrating vectors (lentivirus and retrovirus), we utilize self-inactivating (SIN) designs that eliminate enhancer-promoter activity in the long terminal repeats (LTRs), reducing the risk of insertional mutagenesis. We also employ chromatin insulators to minimize positional effects and potential activation of nearby oncogenes. Our AAV vectors predominantly remain episomal with extremely low integration frequency, while our adenovirus vectors are strictly episomal. All our vectors are produced using systems that minimize the generation of replication-competent viruses through segregation of viral genes across multiple plasmids. We also conduct comprehensive biosafety testing including RCA assays to ensure vector safety.
Yes, we offer extensive capsid engineering services to redirect viral tropism toward specific tissues or cell types. For AAV vectors, we employ both rational design approaches based on structural knowledge and directed evolution platforms that select for capsid variants with enhanced tropism for particular cell types from diverse capsid libraries.
Our production timelines vary based on the vector type, complexity, and quantity required. Standard research-grade batches of lentivirus or adenovirus are typically delivered within 4-6 weeks from project initiation, while AAV vectors generally require 6-8 weeks due to more complex purification and characterization requirements.
Connect with Us Anytime!
As the field continues to evolve, we remain committed to pushing the boundaries of what is possible with viral vector technology, particularly through enhancements in targeting specificity, payload capacity, and manufacturing scalability. We invite you to partner with us in advancing your research programs, leveraging our expertise to accelerate your path to meaningful scientific outcomes. Please feel free to contact us for further discussion with our scientists. Looking forward to cooperating with you.
Start Your Project Today
Tell us about your project, and our experts will get back to you with a customized quote and proposal.
